The Southern African Journal of Anaesthesia and Analgesia (SAJAA) is the official journal of the South African Society of Anaesthesiologists (SASA). The SAJAA is distributed to the most influential role players and decision makers in this therapeutic field. Anaesthesiologists rely on the SAJAA to provide them with review articles, case studies and original research, written by key opinion leaders, on a wide range of topics that affect their daily clinical practice. The SAJAA is utilised by SASA to publish and update national guidelines, and is the official publication of the annual SASA congress.

SAJAA (January – June 2017) | 2 202

Novartis urges patients to play a role in safer medical treatment

NOVARTIS URGES PATIENTS TO PLAY A ROLE IN SAFER MEDICAL TREATMENT Marking World Patient Safety Day, Novartis calls on patients be proactive about communication and adverse event reporting Novartis South Africa has urged South Africans to become more involved in...

Award-winning DOC-U-MENTALLY film now available on DVD

AWARD-WINNING DOC-U-MENTALLY FILM NOW AVAILABLE ON DVD Doc-U-Mentally – an award-winning film about the extreme pressures junior doctors face in South Africa is now available on DVD for R200. The documentary that was produced and directed by Francois Wahl, follows the...

EthiQal 1st Birthday

A new take on medical professional indemnity (PI) protection for doctors is turning the traditional, controversial indemnity insurance model on its head.

HIV prevention possible for those at high risk: men who have sex with men and transgender people

Right to Care, with the support of the Global Fund to Fight AIDS, TB and Malaria is rolling out Pre-Exposure Prophylaxis (PrEP) at three sites in Gauteng and one in the Western Cape, targeting those at high risk for HIV exposure particularly men who have sex with men and transgender people.

Eye strain the new affliction of the digital generation

While digital device usage is soaring, global awareness of digital eye strain is low, according to a new international survey carried out by Novartis among 6,000 people.